Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection

Cytokine

Volumn 60, Issue 1, 2012, Pages 138-142

  Sousa, Gabriel M ^a   Oliveira, Isabela S ^a   Andrade, Luis J O ^b   Sousa Atta, Maria Luiza B ^a   Paraná, Raymundo ^a   Atta, Ajax M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Universidade de Santa Cruz   (Brazil)

Author keywords

Cytokine; Hepatitis c; Liver histology; Th17; Viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHOLIPID ANTIBODY; SMOOTH MUSCLE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROINFLAMMATION; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH17 CELL; VIREMIA; VIRUS LOAD;

ADULT; AGED; ALANINE TRANSAMINASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; LIVER; MALE; MIDDLE AGED; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84865404091     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.003     Document Type: Article

References (33)

1. Rowan A.G., Fletcher J.M., Ryan E.J., Moran B., Hegarty J.E., O'Farrelly C., et al. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 2008, 181:4485-4494.
2. Dambacher J., Beigel F., Zitzmann K., Heeg M.H., Göke B., Diepolder H.M., et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008, 41:209-216.
3. Chang Q., Wang Y.K., Zhao Q., Wang C.Z., Hu Y.Z., Wu B.Y. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol 2011, 10.1111/j.1440-1746.2011.06782.x.
4. Atta A.M., Oliveira I.S., Sousa G.M., Paraná R., Sousa Atta M.L. Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies. Microb Pathog 2010, 48:53-56.
5. Dardalhon V., Korn T., Kuchroo V.K., Anderson A.C. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008, 31:252-256.
6. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol 2010, 32:43-53.
7. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
8. Witthöft T., Möller B., Wiedmann K.H., Mauss S., Link R., Lohmeyer J., et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice. The German open safety trial. J Viral Hepat 2007, 14:788-796.
9. Verma V., Chakravarti A., Kar P. Cytokine levels of TGF-beta, IL-10, and sTNF alphaRII in type C chronic liver disease. Dig Dis Sci 2008, 53:2233-2237.
10. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
11. Kanzler S., Baumann M., Schirmacher P., Dries V., Bayer E., Gerken G., et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001, 8:430-437.
12. Antonelli A., Ferri C., Ferrari S.M., Ghiri E., Marchi S., Colaci M., et al. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin Rheumatol 2009, 28:1179-1185.
13. Feldmann G., Nischalke H.D., Nattermann J., Banas B., Berg T., Teschendorf C., et al. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12:4491-4498.
14. Streetz K.L., Luedde T., Manns M.P., Trautwein C. Interleukin 6 and liver regeneration. Gut 2000, 47:309-312.
15. Liu Y., Li P.K., Li C., Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 2010, 285:27429-27439.
16. Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011, 34:149-162.
17. Wolk K., Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17:367-380.
18. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647-659.
19. Liang S.C., Nickerson-Nutter C., Pittman D.D., Carrier Y., Goodwin D.G., Shields K.M., et al. IL-22 induces an acute-phase response. J Immunol 2010, 185:5531-5538.
20. Hammerich L., Heymann F., Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol 2011, 2011:345803.
21. Zenewicz L.A., Flavell R.A. Recent advances in IL-22 biology. Int Immunol 2011, 23:159-163.
22. Xie Y., Sheng W., Xiang J., Ye Z., Yang J. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest 2010, 28:598-607.
23. Jiang R., Tan Z., Deng L., Chen Y., Xia Y., Gao Y., et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011, 10.1002/hep. 24486.
24. Lan R.Y., Salunga T.L., Tsuneyama K., Lian Z.X., Yang G.X., Hsu W., et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009, 32:43-51.
25. Youinou P., Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 2009, 32:206-210.
26. Aricha R., Mizrachi K., Fuchs S., Souroujon M.C. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011, 36:135-141.
27. Hot A., Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011, 70:727-732.
28. Crispín J.C., Tsokos G.C. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 2010, 22:499-503.
29. Zhao L., Tang Y., You Z., Wang Q., Liang S., Han X., et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 2011, 6(4):e18909.
30. Gregorio G.V., Choudhuri K., Ma Y., Pensati P., Iorio R., Grant P., et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003, 133:404-413.
31. Al-Wabel A., al-Knawy B., Raziuddin S. Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis. Clin Immunol Immunopathol 1995, 74:231-235.
32. Zarife M.A., Reis E.A., Meira G.C., Carmo T.M., Lopes G.B., Malafaia E.C., et al. IL-8 is associated with non-viremic state and IFN-γ with biochemical activity in HCV-seropositive blood donors. Intervirology 2011, 54:87-96.
33. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001, 75:6209-6211.